Dermata Therapeutics, Inc. (DRMA) — Institutional Holders, Q2 2026
15 institutional investment managers reported a DRMA position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $173.5K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
DRMA in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- STATE STREETNew · +18,747 sh+$24.2K
- SUSQUEHANNA INTERNATIONAL GROUP, LLPNew · +15,989 sh+$20.6K
- XTX Topco LtdNew · +14,787 sh+$19.1K
- Advisory AlphaNew · +10,000 sh+$12.9K
- Tower Research Capital (TRC)Added · +3,144 sh+$4.1K
Biggest sellers
- GEODE CAPITAL MANAGEMENTTrimmed · -28,131 sh-$36.3K
- UBS Group AGTrimmed · -18,312 sh-$23.6K
- CITIGROUPSold out · -1 sh-$1.00
DRMA 13F holders ranked 1–15 of 15
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT#1 · 20,203 sh | 20,203 | $26.1K | 0.00% | -58.2% |
| 2 | WELCH & FORBES#2 · 20,000 sh | 20,000 | $25.8K | <0.01% | 0.0% |
| 3 | STATE STREET#3 · 18,747 sh | 18,747 | $24.2K | 0.00% | New |
| 4 | UBS Group AG#4 · 18,600 sh | 18,600 | $21.7K | 0.00% | -49.6% |
| 5 | SUSQUEHANNA INTERNATIONAL GROUP, LLP#5 · 15,989 sh | 15,989 | $20.6K | 0.00% | New |
| 6 | XTX Topco Ltd#6 · 14,787 sh | 14,787 | $19.1K | <0.01% | New |
| 7 | BOOTHBAY FUND MANAGEMENT#7 · 12,000 sh | 12,000 | $15.5K | <0.01% | 0.0% |
| 8 | Advisory Alpha#8 · 10,000 sh | 10,000 | $12.9K | <0.01% | New |
| 9 | Tower Research Capital (TRC)#9 · 3,860 sh | 3,860 | $5.0K | <0.01% | +439.1% |
| 10 | MCF Advisors#10 · 1,732 sh | 1,732 | $2.2K | <0.01% | 0.0% |
| 11 | BARCLAYS PLC#11 · 270 sh | 270 | $348.00 | 0.00% | New |
| 12 | SBI Securities , Ltd.#12 · 101 sh | 101 | $130.00 | — | 0.0% |
| 13 | HIGHLINE WEALTH PARTNERS#13 · 26 sh | 26 | $34.00 | — | New |
| 14 | MORGAN STANLEY#14 · 2 sh | 2 | $3.00 | 0.00% | New |
| 15 | Virtu Financial#15 · 11,029 sh | 11,029 | $0.00 | 0.00% | New |
Funds that sold out of DRMA in Q2 2026 (1)
Held DRMA at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| CITIGROUP1 sh | 1 | $1.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.